Trial Outcomes & Findings for Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE) (NCT NCT03963531)

Results Overview

Interval between the diagnosis of metastatic disease or the first-line systemic therapy onset and the time of death.

Recruitment status

COMPLETED

Target enrollment

545 participants

Primary outcome timeframe

5 years

Results posted on

2025-12-10

Participant Flow

Participant milestones

Participant milestones
Measure	Metastatic Osteosarcoma Patients aged ≥ 12 years 1/ with a diagnosis of osteosarcoma made by an expert pathologist from one of the French network centers (RESOS), 2/ with an initial diagnosis made from 2008 to 2018, 3/ with a metastatic disease (either synchronous or metachronous), 4/ treated in one of the 11 participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Metastatic Chondrosarcoma Patients aged ≥12 years (1) with a diagnosis of chondrosarcoma made by an expert pathologist from one of the French network centers, (2) with an initial diagnosis made from 2008 to 2018, (3) with a metastatic disease (either synchronous or metachronous), (4) treated in one of the nine participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Ewing's Sarcoma Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.
Overall Study STARTED	262	127	156
Overall Study COMPLETED	262	127	156
Overall Study NOT COMPLETED	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Metastatic Osteosarcoma n=262 Participants Patients aged ≥ 12 years 1/ with a diagnosis of osteosarcoma made by an expert pathologist from one of the French network centers (RESOS), 2/ with an initial diagnosis made from 2008 to 2018, 3/ with a metastatic disease (either synchronous or metachronous), 4/ treated in one of the 11 participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Metastatic Chondrosarcoma n=127 Participants Patients aged ≥12 years (1) with a diagnosis of chondrosarcoma made by an expert pathologist from one of the French network centers, (2) with an initial diagnosis made from 2008 to 2018, (3) with a metastatic disease (either synchronous or metachronous), (4) treated in one of the nine participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Ewing's Sarcoma n=156 Participants Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Total n=545 Participants Total of all reporting groups
Age, Continuous	27 years n=262 Participants	63 years n=127 Participants	21 years n=156 Participants	40 years n=545 Participants
Sex: Female, Male Female	112 Participants n=262 Participants	43 Participants n=127 Participants	44 Participants n=156 Participants	199 Participants n=545 Participants
Sex: Female, Male Male	150 Participants n=262 Participants	84 Participants n=127 Participants	112 Participants n=156 Participants	346 Participants n=545 Participants
Race and Ethnicity Not Collected	—	—	—	0 Participants Race and Ethnicity were not collected from any participant.
Region of Enrollment France	262 participants n=262 Participants	127 participants n=127 Participants	156 participants n=156 Participants	389 participants n=545 Participants

PRIMARY outcome

Timeframe: 5 years

Interval between the diagnosis of metastatic disease or the first-line systemic therapy onset and the time of death.

Outcome measures

Outcome measures
Measure	Metastatic Osteosarcoma n=262 Participants Patients aged ≥ 12 years 1/ with a diagnosis of osteosarcoma made by an expert pathologist from one of the French network centers (RESOS), 2/ with an initial diagnosis made from 2008 to 2018, 3/ with a metastatic disease (either synchronous or metachronous), 4/ treated in one of the 11 participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Metastatic Chondrosarcoma n=127 Participants Patients aged ≥12 years (1) with a diagnosis of chondrosarcoma made by an expert pathologist from one of the French network centers, (2) with an initial diagnosis made from 2008 to 2018, (3) with a metastatic disease (either synchronous or metachronous), (4) treated in one of the nine participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Ewing's Sarcoma n=156 Participants Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.
Overall Survival (OS)	21.5 months Interval 18.9 to 27.0	12.7 months Interval 8.2 to 14.9	26.6 months Interval 21.0 to 32.0

PRIMARY outcome

Timeframe: 5 years

time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first

Outcome measures

Outcome measures
Measure	Metastatic Osteosarcoma n=262 Participants Patients aged ≥ 12 years 1/ with a diagnosis of osteosarcoma made by an expert pathologist from one of the French network centers (RESOS), 2/ with an initial diagnosis made from 2008 to 2018, 3/ with a metastatic disease (either synchronous or metachronous), 4/ treated in one of the 11 participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Metastatic Chondrosarcoma n=127 Participants Patients aged ≥12 years (1) with a diagnosis of chondrosarcoma made by an expert pathologist from one of the French network centers, (2) with an initial diagnosis made from 2008 to 2018, (3) with a metastatic disease (either synchronous or metachronous), (4) treated in one of the nine participating national reference centers designated by the French National Cancer Institute for the management of bone sarcomas Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.	Ewing's Sarcoma n=156 Participants Any cancer treatment: chemotherapy, surgery, radiotherapy, interventional radiology.
Time to Next Treatment (TNT)	8.2 months Interval 6.7 to 9.9	4.6 months Interval 3.0 to 5.9	12.5 months Interval 10.4 to 15.6

Adverse Events

Metastatic Osteosarcoma

Serious events: 0 serious events

Other events: 0 other events

Deaths: 172 deaths

Metastatic Chondrosarcoma

Serious events: 0 serious events

Other events: 0 other events

Deaths: 93 deaths

Ewing's Sarcoma

Serious events: 0 serious events

Other events: 0 other events

Deaths: 115 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Simone Mathoulin-Pélissier, Director of Clinical Trials unit

Institut Bergonié, Comprehensive Cancer Center, Bordeaux, FR

Phone: +33 5 56 33 33 33

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place